Posttransplantation lymphoproliferative disorder.

Gastrointest Endosc

Department of Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, Illinois, USA.

Published: February 2005

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0016-5107(04)02573-8DOI Listing

Publication Analysis

Top Keywords

posttransplantation lymphoproliferative
4
lymphoproliferative disorder
4
posttransplantation
1
disorder
1

Similar Publications

Background: Long-term renal allograft acceptance has been achieved in macaques using a transient mixed hematopoetic chimerism protocol, but similar regimens have proven unsuccessful in heart allograft recipients unless a kidney transplant was performed simultaneously. Here, we test whether a modified protocol based on targeting CD154, CD2, and CD28 is sufficient to prolong heart allograft acceptance or promote the expansion of regulatory T cells.

Methods: Eight macaques underwent heterotopic allo-heart transplantation from major histocompatibility complex-mismatched donors.

View Article and Find Full Text PDF

Post-transplant lymphoproliferative disorders (PTLD) are complications that arise from post-transplantation immunosuppressive therapy. Although Epstein-Barr virus (EBV) viremia is often seen in PTLD, it is not a definitive feature for diagnosis. We report a rare case of recurrent PTLD in a 26-year-old heart transplant recipient on high-dose tacrolimus who presented with emesis, fatigue, and bloody diarrhea.

View Article and Find Full Text PDF
Article Synopsis
  • Letermovir (LTV) prophylaxis significantly reduces the incidence of clinically significant cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • A study of 230 patients показал that those receiving LTV experienced a higher rate of Epstein-Barr virus (EBV) reactivation (27%) compared to those who did not receive LTV (13%).
  • Despite the increased EBV reactivation, there were no major differences in recovery metrics, overall survival, or other complications between the LTV and control groups, suggesting a possible link between LTV use and increased EBV reactivation post-transplant.
View Article and Find Full Text PDF
Article Synopsis
  • Post-transplant lymphoproliferative disorder (PTLD) often occurs in patients who have undergone organ or stem cell transplants and is linked to Epstein-Barr virus (EBV) infection, which precedes PTLD in 90% of cases.
  • A study involved pediatric kidney transplant recipients (PKTR) who were monitored for EBV through blood tests, and those with rising viral loads despite lowering immunosuppressive drugs were given preventive rituximab therapy.
  • Results showed that rituximab was effective in clearing EBV from patients who struggled to respond to other treatments, suggesting that it may be a safe option for preventing PTLD in high-risk pediatric kidney transplant patients.
View Article and Find Full Text PDF

Viral infection after hematopoietic stem cell transplantation.

Curr Opin Hematol

November 2024

Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Department of Cellular Therapy and allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.

Purpose Of Review: Viral infections are important complications after allogeneic hematopoietic stem cell transplantation. New infections develop such as SARS-CoV-2 with the potential for severe consequences. In this review, newly published information regarding management of viral infections is discussed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!